Article
Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
Blood advances - 10 Mar 2020
Ediriwickrema Asiri, Aleshin Alexey, Reiter Johannes G, Corces M Ryan, Köhnke Thomas, Stafford Melissa, Liedtke Michaela, Medeiros Bruno C, Majeti Ravindra
Abstract excerpt
Although most patients with acute myeloid leukemia (AML) achieve clinical remission with induction chemotherapy, relapse rates remain high. Next-generation sequencing enables minimal/measurable residual disease (MRD) detection; however, clinical significance is limited due to difficulty differentiating between pre-leukemic clonal hematopoiesis and frankly malignant clones. Here, we investigated AML MRD using...
Topics
Join the communities discussing this publication.
